OBJECTIVE: To compare cycle outcomes among normal-responding patients <or=30 years old receiving microdose follicular flare (MDF) and long-luteal agonist (LL). DESIGN: Retrospective cohort study. SETTING: Military-based assisted reproductive technology (ART) center. PATIENT(S): First autologous ART cycles among 499 women <or=30 years old from January 1999 to December 2005. INTERVENTION(S): After oral contraceptive pill (OCP) administration before cycle start, patients were nonrandomly assigned to either LL or MDF for LH surge suppression. Patients in the LL group received 1 mg/day leuprolide acetate (LA) on cycle day 21, which was reduced to 0.25 mg/day 10-14 days later. Patients in the MDF group received LA (40 microg twice a day) beginning 3 days after discontinuing OCPs. Both groups received a combination of hMG and recombinant FSH. MAIN OUTCOME MEASURE(S): Primary outcomes were implantation, clinical pregnancy, and live-birth rates; in-cycle variables included peak E(2), oocytes retrieved, oocyte maturity, and fertilization rate. RESULT(S): Multivariable models controlling for confounding by treatment indication found no significant differences between groups in implantation (MDF, 36%; LL, 38%), clinical pregnancy (MDF, 53%; LL, 56%), and live-birth rates (MDF, 47%; LL, 50%). No differences were observed in peak E(2), oocytes retrieved, oocyte maturity, fertilization rate, or embryos transferred. CONCLUSION(S): MDF use among normal-responding ART patients produced no differences in cycle outcome when compared with LL. Therefore, MDF may be a viable alternative for normal-responding patients.
OBJECTIVE: To compare cycle outcomes among normal-responding patients <or=30 years old receiving microdose follicular flare (MDF) and long-luteal agonist (LL). DESIGN: Retrospective cohort study. SETTING: Military-based assisted reproductive technology (ART) center. PATIENT(S): First autologous ART cycles among 499 women <or=30 years old from January 1999 to December 2005. INTERVENTION(S): After oral contraceptive pill (OCP) administration before cycle start, patients were nonrandomly assigned to either LL or MDF for LH surge suppression. Patients in the LL group received 1 mg/day leuprolide acetate (LA) on cycle day 21, which was reduced to 0.25 mg/day 10-14 days later. Patients in the MDF group received LA (40 microg twice a day) beginning 3 days after discontinuing OCPs. Both groups received a combination of hMG and recombinant FSH. MAIN OUTCOME MEASURE(S): Primary outcomes were implantation, clinical pregnancy, and live-birth rates; in-cycle variables included peak E(2), oocytes retrieved, oocyte maturity, and fertilization rate. RESULT(S): Multivariable models controlling for confounding by treatment indication found no significant differences between groups in implantation (MDF, 36%; LL, 38%), clinical pregnancy (MDF, 53%; LL, 56%), and live-birth rates (MDF, 47%; LL, 50%). No differences were observed in peak E(2), oocytes retrieved, oocyte maturity, fertilization rate, or embryos transferred. CONCLUSION(S): MDF use among normal-responding ART patients produced no differences in cycle outcome when compared with LL. Therefore, MDF may be a viable alternative for normal-responding patients.
Authors: R M Janssens; C B Lambalk; J P Vermeiden; R Schats; J M Bernards; L T Rekers-Mombarg; J Schoemaker Journal: Hum Reprod Date: 2000-11 Impact factor: 6.918
Authors: André C D van Loenen; Judith A F Huirne; Roel Schats; Peter G A Hompes; Cornelis B Lambalk Journal: Semin Reprod Med Date: 2002-11 Impact factor: 1.303
Authors: Torie C Plowden; Micah J Hill; Shana M Miles; Benjamin Hoyt; Belinda Yauger; James H Segars; John M Csokmay; Rebecca J Chason Journal: Reprod Sci Date: 2016-09-21 Impact factor: 3.060
Authors: George Patounakis; Meghan C Ozcan; Rebecca J Chason; John M Norian; Mark Payson; Alan H DeCherney; Belinda J Yauger Journal: Fertil Steril Date: 2016-04-14 Impact factor: 7.329
Authors: John M Csokmay; Micah J Hill; Rebecca J Chason; Sasha Hennessy; Aidita N James; Jacques Cohen; Alan H Decherney; James H Segars; Mark D Payson Journal: Fertil Steril Date: 2011-07-20 Impact factor: 7.329
Authors: Brian W Whitcomb; Renée Turzanski-Fortner; Kevin S Richter; Simon Kipersztok; Robert J Stillman; Michael J Levy; Eric D Levens Journal: Fertil Steril Date: 2010-07-21 Impact factor: 7.329
Authors: Gary Levy; Micah J Hill; Christina Ramirez; Torrie Plowden; Justin Pilgrim; Robin S Howard; James H Segars; John Csokmay Journal: Fertil Steril Date: 2013-01-30 Impact factor: 7.329
Authors: Micah J Hill; Rebecca J Chason; Mark D Payson; James H Segars; John M Csokmay Journal: Reprod Biomed Online Date: 2012-05-23 Impact factor: 3.828